LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Inicio・Lista de Acciones・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Cerrado

SectorSanidad

11.41 5.65

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

10.8

Máximo

11.6

Métricas clave
By Trading Economics
Ingresos	227M
Ventas	139M
P/B Media del Sector	4.522 50.102
Margen de beneficios	163.843
Empleados	1,796
EBITDA	1.3M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+46.72% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	2.1B
Apertura anterior	5.76
Cierre anterior	11.41

Noticias sobre sentimiento de mercado

By Acuity

10%

90%

8 / 344 Clasificación en Healthcare

Hutchison China MediTech Ltd ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 jun 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 jun 2026, 23:38 UTC

Adquisiciones, fusiones, absorciones

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 jun 2026, 23:37 UTC

Charlas de Mercado

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 jun 2026, 23:01 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

1 jun 2026, 23:01 UTC

Charlas de Mercado

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 jun 2026, 22:08 UTC

Adquisiciones, fusiones, absorciones

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 jun 2026, 22:01 UTC

Adquisiciones, fusiones, absorciones

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 jun 2026, 22:01 UTC

Adquisiciones, fusiones, absorciones

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 jun 2026, 21:55 UTC

Adquisiciones, fusiones, absorciones

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 jun 2026, 21:53 UTC

Charlas de Mercado

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 jun 2026, 21:22 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 jun 2026, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

1 jun 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

1 jun 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

1 jun 2026, 20:46 UTC

Adquisiciones, fusiones, absorciones

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 jun 2026, 20:22 UTC

Adquisiciones, fusiones, absorciones

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 jun 2026, 20:21 UTC

Adquisiciones, fusiones, absorciones

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 jun 2026, 20:21 UTC

Adquisiciones, fusiones, absorciones

Array Digital Infrastructure Declares $11 Special Div

1 jun 2026, 20:20 UTC

Adquisiciones, fusiones, absorciones

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 jun 2026, 19:40 UTC

Charlas de Mercado

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 jun 2026, 19:28 UTC

Charlas de Mercado

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 jun 2026, 19:01 UTC

Charlas de Mercado

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 jun 2026, 18:58 UTC

Charlas de Mercado

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 jun 2026, 18:54 UTC

Adquisiciones, fusiones, absorciones

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 jun 2026, 18:33 UTC

Charlas de Mercado

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 jun 2026, 18:32 UTC

Charlas de Mercado

Precious Metals Fall to Start June -- Market Talk

1 jun 2026, 18:00 UTC

Adquisiciones, fusiones, absorciones

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 jun 2026, 17:18 UTC

Charlas de Mercado

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 jun 2026, 17:18 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

1 jun 2026, 17:10 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Comparación entre iguales

Cambio de precio

Hutchison China MediTech Ltd ADR previsión

Precio Objetivo

By TipRanks

46.72% repunte

Estimación a 12 Meses

Media 16.8 USD 46.72%

Máximo 20 USD

Mínimo 13.6 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Sentimiento

By Acuity

8 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.